Category: Doctors Corners

Jim Tananbaum’s Foresite Capital Helps Mindstrong Health in Raising $14m from a Series A Financing Round

Jim Tananbaum is an entrepreneur and the creative force behind a venture capital company known as Foresite Capital. The venture capital company usually focuses on enabling healthcare companies to raise capital. Mindstrong Health, a neuropsychiatric treatment and diagnosis firm, is the latest beneficiary of Foresite Capital’s services. Mindstrong managed to raise $14 million from a Series A financing round led by Foresite.

Mindstrong’s AI Platform

According to INC42, the money is set to support Mindstrong’s neuropsychiatric treatment and diagnosis platform. The platform comprises of an artificial intelligence functionality designed to monitor interaction patterns and brain function on smartphones effectively. It focuses on providing continuous and consistent digital biomarkers of cognition and mood. These biomarkers include processing speed, memory, executive function, and attention.

Dr. Tom Insel is one of the creative forces behind the success of Mindstrong Health. He said that the company’s approach to assessing brain function acts as a foundation for developing treatments to improve mental health. He also pointed out that the AI platform can monitor one’s scrolling and typing patterns on a smartphone. Insel believes that smartphones can be used in diagnosing some of the most complicated cognitive disorders. Check out Ideamensch to know more.

Besides Foresite Capital, the financial round was also led by ARCH Venture Partners, the One Mind Brain Health Impact Fund, Berggruen Holdings, and Optum Ventures. Jim Tananbaum said that Mindstrong Health comprises of experts who understand the challenges that modern health facilities face when addressing cognitive health disorders. He said that the firm’s leadership team has a collective experience that can be used to improve the manner in which care is offered to patients with such disorders.

About Jim Tananbaum

Besides Foresite Capital, Jim Tananbaum also founded and headed several venture capital firms. These include Intarcia Therapeutics and Puma Biotechnology. Tananbaum is also celebrated as the founding partner of a privately owned company called Prospect Venture Partners I and II.

Tananbaum is also the brains behind a healthcare company, which has a market cap of $3.5 billion, known as Theravance. He acted as the company’s CEO before coming up with Foresite Capital. As he commenced his professional career, Tananbaum was Sierra Ventures’ partner. He helped the firm in establishing its first healthcare service investment practice.

See more: http://www.businesswire.com/news/home/20170418005997/en/Foresite-Capital-Announces-CEO-Jim-Tananbaum-Named

Top Reasons To Seek Medical Treatment From The Award-Winning Hospital Copa Star

Getting sick is often the worst of times. Being sick to the extent that you need to get admitted to a hospital is outright petrifying to most, if not all, of us. The fear comes from two aspects mostly. One, are there world-class services and products at the premises you have to call your home for God knows how long? Secondly, will the stay at the hospital end up bankrupting you entirely? These are just of the valid concerns one has when faced with the possibility of dealing with many of the existing medical facilities in 2017. There’s a silver-lining, however, somewhere in there between those dark clouds of institutions and it’s called the Copa Star Hospital Complex. View the design at RafArquitetura.Com

Homely Rooms for Speedy Recovery

Several studies have already proven without an ounce of doubt that there’s a strong connection between recovery and the environment of a patient. Place a recuperating person in a modern, clean space where every minute they have a trained professional watching and monitoring their signs of progress and in a week or so, they are back to their healthy, normal selves. The Copa Star takes the phrase, ‘royal hospitality’ to the next level by having private apartments to house their patients instead of the squeezed cubicles you would expect to find in a public health facility in New York or elsewhere in the nation. Not just that, but the apartments don’t have that characteristic bland-monotonous look and feel of your regular hospital. No, the place has enormous-sized patient facilities which often come with one of the strangest things you would ever expect to find in any hospital in the world: Windows with direct views of the Copacabana Beaches.

Costs of Services at Copa Star

It’s all fine and dandy to have a recovery space where everything looks like a scene out of a hotel in Dubai but, lest we get too carried away; we went there to get cured and healed from whatever it is that ails us. The success of our healing process depends mostly on the ability and skills of the staff working at a particular health center. At Copa Star, the seasoned professionals in charge of running the day-to-day activities of the international health care service provider have already come up with a brilliant solution to the frequent complications experienced at Brazilian hospitals.

About Copa Star

The administration has signed off on the acquisition of some of the latest, cutting-edge technology to make an accurate diagnosis for their patients. Contrary to popular sentiment, the premises founded in 2016 are not expensive. Factoring in what you get at the premises, the cost charged for the various surgical procedures is just but a small token of appreciation to the life-saving help you end up receiving. Visit their official website and learn more about their personalized health care management and approach strategies. Read more at Scoopnest about Copa Star.

Oncotarget’s Success In Publishing Different Fields Beyond Oncology

Oncotarget is a multidisciplinary traditional journal having free access. The weekly issue publishes papers online. The word “oncology” entails all cellular functions present in cancer and aging, lymphocytes and neurons, microbes and cancer cells. The rising popularity of Oncotarget is informed by its insightful, constructive, punctual and multiple peer-review that helps the authors to increase the impact of their research. Since 2013, four authors that publish their articles through Oncotarget, Bert Vogelstein, Michael N. Hall, Alexander Varshavsky, Stephen J. Elledge, won the Breakthrough Prize. View Mikhail’s profile in LinkedIn

Oncotarget’s mission is to make scientific results to be widely available and accessible. In addition, the journal maximizes the impact of research through insightful reviews that enhances the sharing of different discoveries quickly. The management of the journal is seeking to eliminate the boundaries between various specialties. They are also aiming to publish various topics in biomedical science. Most articles have been discussing about the use of clinical science to treat different ailments. Through the leadership of the prominent scientists, the journal has been able to help different researchers to make positive contributions in their respective fields of specialization. Most researchers seek to develop different therapies that can be used to cure different diseases. The success of Oncotarget has resulted in the publication of different topics beyond oncology

Oncotarget was established in 2010. Mikhail Blagosklonny and Andrei V. Gudkov are the editors-in-chief of the revered journal. Mikhail Blagosklonny is a renowned scientist who researches on cancer and aging. He was a professor of oncology at Roswell Park Cancer Institute in New York. Blagosklonny earned both his M.D in internal medicine and PhD in experimental medicine and cardiology from the First Pavlov State Medical University of St. Petersburg. Blagosklonny’s research zeroes in on cancer and targeted cancer therapies that protect normal cells from damage, as well as the underlying mechanisms of aging and anti-aging drugs.

Oncotarget applies the Creative Commons Attribution License to all the works that they publish. Under the CC BY, authors retain ownership of the copyright for their articles. However, they allow anyone to download, reuse, reprint, modify, distribute and copy articles, provided the original authors and sources of information are cited appropriately. Visit ResearchGate.Net to learn more about Mikhail’s latest work.

COULD THIS BE THE AWAITED BREAKTHROUGH FOR TREATING MULTIPLE SCLEROSIS?

The Medicine profession is considered technical. Neurologists such as Dr. Shiva Gopal Vasishita, for instance, are specifically trained in the diagnosis and treatment of nervous system disorders including ailments of the brain, spinal cord, nerves, and muscles. They are subjected to a rigorous education system meant to build their capacity of the complexities that await them in neurology.

Dr.Shiva Gopal Vasishita happens to be one of the practicing neurologists we have today. He graduated from Government Medical College in 1979 and has been practicing both neurology and psychiatry for 40years now in Voorhees, New Jersey. Dr. Shiva is affiliated with Kennedy Health System Cherry Hill Campus. In his line of work, Dr. Shiva plays a vital role in explaining the mechanisms of a traumatic brain injury, the results of clinical examination and the significance of diagnostic test results.

On 1st February 2017, the National Institute of Health disclosed that evidence from recent trials suggested that high-dose immunosuppressive therapy then a transplant of a person’s blood- forming stem cells had the ability to induce sustained remission of relapsing-remitting multiple sclerosis. This is an autoimmune disease in which a person’s immune system attacks the central nervous system. 69 percent of the trial participants survived without experiencing progression of disability, relapsing of MS syndrome or new brain lesions five years later after receiving high-dose immunosuppressive therapy and autologous hematopoietic cell transplant (HDIT/HCT). The participants did not need any MS medication after receiving HDIT/HCT.

The trial that was sponsored by the National Institute of Allergy and Infectious Diseases (NIAD) published the final five-year results in Neurology- the medical journal of the American Academy of Neurology on 1st February.

The possibility of a one-time HDIT/HCT treatment being substantially more effective than long-term treatment with medications for Multiple Sclerosis is great news for neurologists such as Dr. Shiva who are committed to getting breakthroughs in solving brain diseases.